See more : T-Flex Techvest PCB Co., Ltd. (3276.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of Interpace Biosciences, Inc. (IDXG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Interpace Biosciences, Inc., a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Plymouth Industrial REIT, Inc. (PLYM-PA) Income Statement Analysis – Financial Results
- Monte Rosa Therapeutics, Inc. (GLUE) Income Statement Analysis – Financial Results
- Laird Superfood, Inc. (LSF) Income Statement Analysis – Financial Results
- Trigg Minerals Limited (TMG.AX) Income Statement Analysis – Financial Results
- View, Inc. (VIEWW) Income Statement Analysis – Financial Results
Interpace Biosciences, Inc. (IDXG)
About Interpace Biosciences, Inc.
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States. The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer. The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 40.21M | 31.84M | 41.31M | 32.40M | 24.08M | 21.90M | 15.90M | 13.09M | 9.43M | 119.94M | 150.84M | 126.90M | 157.29M | 144.65M | 84.87M | 112.53M | 117.13M | 239.24M | 319.42M | 364.44M | 317.45M | 284.01M | 696.58M | 416.88M | 174.90M | 101.10M | 54.70M |
| Cost of Revenue | 16.31M | 13.61M | 23.37M | 21.67M | 15.89M | 10.20M | 7.36M | 6.64M | 6.91M | 101.39M | 126.43M | 100.04M | 124.82M | 112.45M | 58.59M | 108.02M | 85.52M | 183.40M | 257.48M | 265.61M | 228.37M | 254.14M | 560.80M | 302.28M | 128.90M | 77.70M | 44.30M |
| Gross Profit | 23.90M | 18.23M | 17.95M | 10.73M | 8.19M | 11.70M | 8.54M | 6.44M | 2.52M | 18.54M | 24.41M | 26.86M | 32.47M | 32.20M | 26.28M | 4.51M | 31.62M | 55.84M | 61.94M | 98.83M | 89.08M | 29.87M | 135.78M | 114.60M | 46.00M | 23.40M | 10.40M |
| Gross Profit Ratio | 59.44% | 57.26% | 43.44% | 33.10% | 34.02% | 53.43% | 53.71% | 49.25% | 26.74% | 15.46% | 16.18% | 21.17% | 20.64% | 22.26% | 30.96% | 4.01% | 26.99% | 23.34% | 19.39% | 27.12% | 28.06% | 10.52% | 19.49% | 27.49% | 26.30% | 23.15% | 19.01% |
| Research & Development | 636.00K | 703.00K | 1.88M | 2.80M | 2.81M | 2.12M | 1.46M | 1.65M | 2.29M | 255.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 9.36M | 10.97M | 13.67M | 20.77M | 14.55M | 8.50M | 9.15M | 10.50M | 16.92M | 29.15M | 28.69M | 27.87M | 34.28M | 36.51M | 48.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 10.23M | 9.13M | 10.07M | 9.25M | 11.12M | 8.42M | 6.57M | 5.46M | 10.36M | 604.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 19.60M | 20.10M | 23.74M | 30.02M | 25.66M | 16.92M | 15.72M | 15.97M | 27.28M | 29.15M | 28.69M | 27.87M | 34.28M | 36.51M | 48.74M | 39.37M | 44.83M | 50.69M | 88.82M | 63.64M | 67.25M | 76.83M | 123.08M | 71.65M | 29.10M | 13.90M | 7.90M |
| Other Expenses | 868.00K | 1.27M | 4.06M | 4.46M | 3.65M | 263.00K | -2.13M | 14.00K | -93.00K | -68.00K | -59.00K | -28.00K | 2.89M | 20.57M | 0.00 | 333.00K | 1.06M | -3.28M | 53.49M | 0.00 | 2.10M | 0.00 | 0.00 | 2.08M | 1.20M | 300.00K | 100.00K |
| Operating Expenses | 20.23M | 22.07M | 29.68M | 37.28M | 32.12M | 22.30M | 20.43M | 21.38M | 33.38M | 29.93M | 28.69M | 27.87M | 37.17M | 36.51M | 48.74M | 39.70M | 45.90M | 47.41M | 88.82M | 63.64M | 69.35M | 76.83M | 123.08M | 73.72M | 30.30M | 14.20M | 8.00M |
| Cost & Expenses | 37.41M | 35.68M | 53.05M | 58.95M | 48.01M | 32.49M | 27.79M | 28.02M | 40.29M | 131.32M | 155.12M | 127.91M | 161.99M | 148.96M | 107.33M | 147.72M | 131.41M | 230.80M | 346.30M | 329.25M | 297.72M | 330.97M | 683.88M | 376.00M | 159.20M | 91.90M | 52.30M |
| Interest Income | 0.00 | 1.01M | 1.04M | 549.00K | 440.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.74M | 3.19M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 1.01M | 1.01M | 920.00K | 549.00K | 440.00K | 331.00K | 433.00K | 2.14M | 3.71M | 602.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.03M | 2.56M | 5.37M | 5.50M | 4.52M | 3.80M | 3.69M | 4.27M | 5.03M | 2.39M | 1.43M | 2.03M | 3.05M | 1.98M | 2.84M | 4.61M | 5.61M | 5.76M | 5.82M | 5.92M | 6.80M | 7.82M | 4.99M | 2.08M | 1.20M | 300.00K | 100.00K |
| EBITDA | 3.84M | -2.27M | -1.33M | -20.10M | -21.72M | -8.57M | -9.01M | -2.16M | -35.47M | -13.35M | -212.00K | 725.00K | -1.67M | -3.08M | -14.16M | -28.97M | -8.67M | 16.42M | -5.39M | 41.89M | 28.08M | -39.59M | 17.70M | 42.95M | 16.90M | 10.00M | 3.00M |
| EBITDA Ratio | 9.54% | -11.88% | -19.80% | -66.75% | -83.41% | -32.34% | -67.75% | -85.25% | -274.86% | -7.55% | -1.89% | 19.90% | -1.04% | -1.71% | -5.33% | -25.78% | -6.50% | 5.62% | -7.99% | 11.07% | 8.73% | -13.34% | 2.21% | 9.14% | 8.35% | 7.42% | 16.45% |
| Operating Income | 2.80M | -3.84M | -11.74M | -26.56M | -23.93M | -12.12M | -6.29M | -6.44M | -40.41M | -13.47M | -4.28M | -25.23M | -4.70M | -4.31M | -40.58M | -36.43M | -14.28M | 5.91M | -26.89M | 35.19M | 19.59M | -50.18M | 12.71M | 40.88M | 15.70M | 9.20M | 2.40M |
| Operating Income Ratio | 6.97% | -12.06% | -28.41% | -81.96% | -99.39% | -55.35% | -39.59% | -49.23% | -428.41% | -11.23% | -2.84% | -19.88% | -2.99% | -2.98% | -47.81% | -32.37% | -12.19% | 2.47% | -8.42% | 9.66% | 6.17% | -17.67% | 1.82% | 9.81% | 8.98% | 9.10% | 4.39% |
| Total Other Income/Expenses | -1.68M | -2.22M | -1.41M | -82.00K | -244.00K | -582.00K | -6.84M | -2.13M | -3.80M | -670.00K | -2.90M | -24.25M | -939.00K | 414.00K | -26.89M | 2.51M | 4.68M | 4.74M | 15.68M | 1.89M | -1.03M | 1.97M | 2.28M | 4.86M | 2.20M | 2.00M | -6.20M |
| Income Before Tax | 1.13M | -5.84M | -15.41M | -26.15M | -26.67M | -12.19M | -13.13M | -8.57M | -44.21M | -14.14M | -4.34M | -25.26M | -4.72M | -4.17M | -40.39M | -33.59M | -8.21M | 10.65M | -19.25M | 35.97M | 20.66M | -48.21M | 14.98M | 45.74M | 17.90M | 11.20M | -4.10M |
| Income Before Tax Ratio | 2.81% | -18.33% | -37.31% | -80.71% | -110.75% | -55.66% | -82.61% | -65.51% | -468.68% | -11.79% | -2.87% | -19.91% | -3.00% | -2.88% | -47.59% | -29.85% | -7.01% | 4.45% | -6.03% | 9.87% | 6.51% | -16.97% | 2.15% | 10.97% | 10.23% | 11.08% | -7.50% |
| Income Tax Expense | 17.00K | 29.00K | -667.00K | 53.00K | -28.00K | 18.00K | -395.00K | -162.00K | -13.14M | -4.74M | 180.00K | 208.00K | -939.00K | 414.00K | -6.83M | 875.00K | 1.77M | -724.00K | 201.00K | 14.84M | 8.41M | -17.45M | 8.63M | 18.71M | 7.50M | 1.70M | 6.60M |
| Net Income | 802.00K | -5.87M | -14.75M | -26.20M | -26.64M | -12.19M | -12.22M | -8.33M | -11.36M | -16.07M | -4.57M | -25.53M | -11.91M | -6.81M | -33.56M | -34.46M | -9.97M | 11.81M | -19.45M | 21.13M | 12.26M | -30.76M | 6.35M | 27.03M | 10.40M | 9.50M | -4.20M |
| Net Income Ratio | 1.99% | -18.42% | -35.69% | -80.87% | -110.63% | -55.67% | -76.84% | -63.68% | -120.40% | -13.40% | -3.03% | -20.12% | -7.57% | -4.71% | -39.54% | -30.62% | -8.52% | 4.94% | -6.09% | 5.80% | 3.86% | -10.83% | 0.91% | 6.48% | 5.95% | 9.40% | -7.68% |
| EPS | 0.19 | -1.38 | -3.57 | -6.50 | -7.11 | -4.33 | -7.77 | -45.88 | -73.38 | -107.87 | -3.10 | -17.50 | -8.25 | -4.76 | -23.60 | -24.20 | -7.15 | 8.50 | -13.67 | 14.00 | 8.40 | -21.92 | 4.60 | 20.00 | 8.70 | 9.20 | -4.86 |
| EPS Diluted | 0.18 | -1.38 | -3.57 | -6.50 | -7.11 | -4.33 | -7.75 | -45.88 | -73.36 | -107.87 | -3.10 | -17.50 | -8.25 | -4.76 | -23.60 | -24.20 | -7.15 | 8.40 | -13.67 | 13.70 | 8.30 | -21.92 | 4.50 | 19.60 | 8.60 | 9.10 | -4.86 |
| Weighted Avg Shares Out | 4.32M | 4.24M | 4.14M | 4.03M | 3.75M | 2.82M | 1.57M | 181.60K | 154.75K | 149.01K | 1.47M | 1.46M | 1.44M | 1.43M | 1.42M | 1.42M | 1.39M | 1.39M | 1.42M | 1.46M | 1.42M | 1.40M | 1.39M | 1.35M | 1.20M | 1.07M | 863.64K |
| Weighted Avg Shares Out (Dil) | 4.36M | 4.24M | 4.14M | 4.03M | 3.75M | 2.82M | 1.58M | 181.60K | 154.80K | 149.01K | 1.47M | 1.46M | 1.44M | 1.43M | 1.42M | 1.42M | 1.39M | 1.40M | 1.42M | 1.49M | 1.44M | 1.40M | 1.41M | 1.38M | 1.22M | 1.08M | 863.64K |
Interpace Biosciences, Inc. (IDXG) Reports Q2 Loss, Tops Revenue Estimates
Interpace Biosciences, Inc. (IDXG) delivered earnings and revenue surprises of -72.92% and 0.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Interpace Biosciences, Inc. (IDXG) Is a Great Choice for "Trend" Investors, Here's Why
Interpace Biosciences, Inc. (IDXG) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price...
Interpace Biosciences Announces First Quarter 2021 Financial and Business Results
PARSIPPANY, NJ, May 11, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended March 31, 2021 and provided a business and financial update.
Interpace Biosciences Raises Full Year 2021 Revenue Guidance
Parsippany, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced an update to its full year 2021 revenue guidance originally provided on March 31, 2021.
Interpace Pharma Solutions Announces New Advanced Offering in RNA Biomarker Analysis
Parsippany, NJ, April 12, 2021 (GLOBE NEWSWIRE) -- Interpace Pharma Solutions, a subsidiary of Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today new capability in advancing RNA biomarker analysis for gene and cell-based therapies.
Interpace Biosciences Announces New PLA Code and Medicare Reimbursement Increase for Proprietary Thyroid Assay, ThyGeNEXT®
Parsippany, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) announced today that Novitas, its Medicare Administrative Contractor, has agreed to recognize the new Proprietary Laboratory Analysis (PLA) code that specifically identifies ThyGeNEXT® as...
Interpace Biosciences Announces Full Year and Fourth Quarter 2020 Financial and Business Results
PARSIPPANY, NJ, March 31, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the fiscal quarter ended December 31, 2020 and provided a business and financial update.
Interpace Biosciences Announces Divestiture of New Haven CLIA lab to DiamiR
Part of Company's Site Consolidation and Cost Savings Measures
Interpace Biosciences Announces Contract for Thyroid Testing with Blue Cross Blue Shield of Illinois
In-network status for ThyGeNEXT® and ThyraMIR® with State's Largest Payer
Interpace Biosciences Announces Acceptance for Trading on the OTCQX
PARSIPPANY, NJ, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCQX: IDXG) (“Interpace Biosciences” or the “Company”), an emerging leader in enabling personalized medicine, today announced that on February 24, 2021, the Company satisfied the requirements for trading of...
Source: https://incomestatements.info
Category: Stock Reports